Keros Therapeutics Inc share price logo

Keros Therapeutics Inc Share Price

NASDAQ: KROS

Small Cap

$15.73

+0.18

(+1.16%)

Live

as on

Keros Therapeutics Inc Stock Performance

as on September 16, 2025 at 7:37 pm IST

  • Day's Low

    Day's High

    $15.52
    $15.79
    downward going graph

    1.34%

    Downside

    0.38%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $9.12
    $72.37
    downward going graph

    42.02%

    Downside

    360.08%

    Upside

    downward going graph

Keros Therapeutics Inc share price movements today

Previous Close
$15.55
Open
$15.52
Volume
30.8K
Day's Low - High
$15.52 - $15.79
52 Week Low - High
$9.12 - $72.37

Keros Therapeutics Inc Historical Returns

1 Month Return
+ 7.39 %
3 Month Return
+ 13.84 %
1 Year Return
-72.04 %
3 Year Return
-57.7 %
5 Year Return
0 %

Keros Therapeutics Inc Stock Fundamentals & Key Indicators

Check Keros Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$636.0M

EPS (TTM)

0.9963

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

48.59

Industry PE ratio

-3.947831325301205

P/B Ratio

48.5938

PEG Ratio

0

EBITDA

1.7M

Revenue (TTM)

232.8M

Profit Margin

8.06%

Return On Equity TTM

3.33%

Keros Therapeutics Inc Stock Valuation

Track how Keros Therapeutics Inc P/E has moved over time to understand its valuation trends.

Keros Therapeutics Inc in the last 5 years

  • Overview

  • Trends

Lowest (43.55x)

June 30, 2025

Industry (-3.95x)

September 16, 2025

Today (48.59x)

September 16, 2025

Highest (43.55x)

June 30, 2025

LowHigh

Today’s Price to Earnings Ratio: 48.59x

Keros Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Keros Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Keros Therapeutics Inc image
Keros Therapeutics Inc
BUY$636.0MNA48.598.06%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$61.1B251.26%-505.15-12.96%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$38.7BNANA-3.89%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$101.2B47.46%28.0931.86%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$59.6B0.6%14.131.37%

Stock Returns calculator for Keros Therapeutics Inc Stock including INR - Dollar returns

The Keros Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Keros Therapeutics Inc investment value today

Current value as on today

₹33,149

Returns

₹66,851

(-66.85%)

Returns from Keros Therapeutics Inc Stock

₹71,719 (-71.72%)

Dollar Returns*

₹4,867 (+4.87%)

Analyst Recommendation on Keros Therapeutics Inc Stock

Based on 16 analysts

BUY

93.75%

Buy

6.25%

Hold

0.00%

Sell

Based on 16 analysts, 93.75% of analysts recommend a 'BUY' rating for Keros Therapeutics Inc. Average target price of $23

Keros Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Keros Therapeutics Inc.

What analysts predicted

31.61%UPSIDE

Target Price

$23

Current Price

$15.73

Analyzed by

16 Analysts

Target

$23.00

Keros Therapeutics Inc target price $23, a slight upside of 31.61% compared to current price of $15.73. According to 16 analysts rating.

Keros Therapeutics Inc Stock's Interest Amongst Investors

Search interest for Keros Therapeutics Inc Stock has increased by 44% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:44% versus previous 30 day period

Keros Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
-
-
0
0
0
0
0
3
211
18
Gross Profit
0
0
0
0
0
0
0
2
211
17
Operating Income
-38
-41
-43
-46
-48
-50
-58
-53
152
-39
EBITDA
-38
-41
-43
-39
-48
-50
-58
-29
152
-39
Interest Expense
3
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-35
-37
-39
-40
-43
-45
-52
-45
158
-32
Income Tax Expense
-3
3
0
3
0
-
-
0
10
-2
Net Income
-32
-37
-39
-40
-43
-45
-52
-46
148
-30
Net Profit Margin
0.00%
0.00%
-493000.00%
-28141.96%
-51944.58%
-122316.22%
-13648.45%
-1513.02%
70.27%
-168.96%

Keros Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
10
10
2
20
20
0
3
Gross Profit
0
-7
0
19
-1
0
3
Operating Income
-1
-10
-46
-56
-114
-169
-210
EBITDA
0
-11
-44
-56
-103
-152
-185
Interest Expense
0
0
0
0
0
-
-
Depreciation
0
0
0
0
0
0
1
Income Before Tax
-1
-12
-45
-56
-104
-152
-187
Income Tax Expense
0
0
0
2
0
0
0
Net Income
-1
-12
-45
-58
-104
-152
-187
Net Profit Margin
-13.35%
-123.44%
-1814.44%
-292.26%
-523.40%
-101319.21%
-5277.55%

Keros Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
-37
-39
-40
-43
-45
-52
-46
148
-30
Operating Cash Flow
-30
-33
-25
-44
-39
-30
-46
161
-29
Investing Cash Flow
0
0
0
0
0
0
0
0
0
Financing Cash Flow
1
0
69
156
3
155
75
0
0
Change in Cash
-29
-34
43
111
-36
125
29
160
-30

Keros Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
-12
-45
-58
-104
-152
-187
Operating Cash Flow
-15
-36
-62
-70
-124
-160
Investing Cash Flow
0
0
-1
-1
-2
-1
Financing Cash Flow
0
296
28
120
178
391
Change in Cash
-16
258
-34
49
51
229

Global Institutional Holdings in Keros Therapeutics Inc

Funds
Holdings
Nuveen, LLC
9.72%
BlackRock Inc
6.86%
JPMorgan Chase & Co
6.4%
Vanguard Group Inc
6.32%
Logos Global Management LP
4.92%
See all

Insights on Keros Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 70.6% return, outperforming this stock by 142.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 116.5% return, outperforming this stock by 174.2%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 year, KROS stock has moved down by -72.0%

About Keros Therapeutics Inc

keros therapeutics, inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. the company's lead protein therapeutic product candidate is ker-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or mds, and in patients with myelofibrosis. it is also developing small molecule product candidate ker-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or fop, and is currently in a phase 1 clinical trial; and ker-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or pah. the company was founded i
OrganisationKeros Therapeutics Inc
Headquarters1050 Waltham Street, Lexington, MA, United States, 02421
IndustryCommercial Services
CEODr. Jasbir S. Seehra Ph.D.
E-voting on sharesClick here to vote

Key Management of Keros Therapeutics Inc

Name

Title

Dr. Jasbir S. Seehra Ph.D.

President, CEO & Director

Mr. Keith C. Regnante MBA

Chief Financial Officer

Ms. Esther Cho J.D.

Senior VP, General Counsel & Secretary

Dr. Lorena Lerner Ph.D.

Chief Scientific Officer

FAQs

What is Keros Therapeutics Inc share price today?

Keros Therapeutics Inc share price today is $15.73 as on . Keros Therapeutics Inc share today touched a day high of $15.79 and a low of $15.52.

What is the 52 week high and 52 week low for Keros Therapeutics Inc share?

Keros Therapeutics Inc share touched a 52 week high of $72.37 on and a 52 week low of $9.12 on . Keros Therapeutics Inc stock price today i.e. is trending at $15.73,which is 78.26% down from its 52 week high and 72.48% up from its 52 week low.

What is Keros Therapeutics Inc's market capitalisation today?

Keros Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in Keros Therapeutics Inc Stock (KROS) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Keros Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Keros Therapeutics Inc Shares that will get you 0.0954 shares as per Keros Therapeutics Inc share price of $15.73 per share as on September 16, 2025 at 7:37 pm IST.

What is the minimum amount required to buy Keros Therapeutics Inc Stock (KROS) from India?

Indian investors can start investing in Keros Therapeutics Inc (KROS) shares with as little as ₹88.042 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹880.42 in Keros Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Keros Therapeutics Inc share’s latest price of $15.73 as on September 16, 2025 at 7:37 pm IST, you will get 0.6357 shares of Keros Therapeutics Inc. Learn more about fractional shares .